tapering off tirzepatide Weaning GLP-1 Medications: A Sustainable Approach Do You Have to Taper

Description

We are moving from: Traditional Vials Pre-Filled Syringes Smart Injection Devices Connected Drug Delivery Systems Personalized Therapy The next billion-dollar opportunity in pharma may not come from discovering a new drug

Semaglutide effectiveness for weight loss depends on formulation choice, dosing consistency, and individual metabolic factors

Insulin resistance and diabetes management

Researchers have found that aging and stress can cause pancreatic cells to become senescent, meaning they stop working properly

The STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial programme demonstrated that adults using semaglutide 2.4 mg weekly alongside lifestyle intervention lost an average of approximately 15% of their body weight over 68 weeks, compared to around 2.4% with placebo. NICE approved Wegovy for use in specialist weight management services in the UK in 2023 (TA875), recognising its clinical effectiveness. Ongoing research continues to explore its cardiovascular benefits, with the SELECT trial showing a significant reduction in major cardiovascular events in people with obesity